Revance Therapeutics’ contract dispute with a Swiss partner has caused hiccups in its plan to be acquired by Crown Laboratories. Now that partner says it can offer Revance a better deal. Teoxane proposed to acquire Revance for $3.60 per share, a 16% premium over Crown’s $3.10-per-share offer. The company said in a letter to Revance’s leadership that its offer is a “superior, attractive and actionable alternative” to Crown’s proposal. Teoxane currently owns 6.2% of Revance’s outstanding shares.
Read the full article: Teoxane Issues Competing Buyout Bid for Revance and Its Botox Rival //
Source: https://endpts.com/teoxane-issues-competing-buyout-bid-for-revance-and-its-botox-rival